课题基金 / 基金详情

Beyond infection: Innate immune receptors as an emerging brake on metastasis

Beyond infection: Innate immune receptors as an emerging brake on metastasis
超越感染:先天免疫受体作为新兴的转移制动剂
批准号:
9230016
负责人:
Sneha Prakash Rath
金额:
$4.51万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-21 至 2018-08-31

项目摘要

项目成果

Sneha Prakash Rath的其他基金

相似基金

相关文献

中文摘要
翻译
超越感染:先天免疫受体作为转移的新刹车
英文摘要
BEYOND INFECTION: INNATE IMMUNE RECEPTORS AS AN EMERGING BRAKE ON METASTASIS ABSTRACT Innate immune signaling is a key mammalian defense against pathogens. Importantly, these signaling networks are critically linked to human disease even outside the realm of infections. This facet of innate immunity remains largely elusive and forms the subject of my research. My thesis focuses on the pseudokinase RNase L, which is most strongly activated during infection. RNase L is triggered by 2'-5'-linked iso-RNAs, produced by oligoadenylate synthetases (OASs) upon sensing double-stranded RNA (dsRNA) commonly thought to come from RNA viruses. RNase L is essential for coping with bacterial and viral infections. RNase L is also a major regulator of cell cycle progression, differentiation, and apoptosis, processes often misregulated in cancers. Notably, many RNase L mutations predispose men to an elevated risk of inherited prostate cancer. Moreover, my preliminary results uncover that dampened RNase L expression strongly correlates with increased breast cancer aggressiveness. The effect of RNase L on tumor suppression is striking but its molecular mechanism is unclear. My work identifies the first cellular targets of human RNase L outside infection, tackling a challenge faced since the discovery of RNase L in 1980. Serendipitously, RNase L targets perfectly overlap with those of a well-established tumor-suppressor, miR-200, and one of their common targets is the master regulator of metastasis, ZEB1. These results suggest a direct molecular mechanism for the role of RNase L in controlling metastasis, which I seek to examine during my F99 phase. In addition, I will isolate endogenous dsRNAs, predicted to be elevated in cancers, which can feed into the OAS/RNase L axis. Thus, I will test if OASs are a dsRNA surveillance mechanism against not only viruses but also cancer. This work will uncover the molecular mechanism for a major non-immune function of the OAS/RNase L axis, informing novel diagnostic and therapeutic strategies against metastasis. My thesis initiates me into the emerging field of innate immunity in cancer and seeds my postdoctoral research directions. With rigorous training and an exciting potential to serve human health, I am on a perfect trajectory to launch an independent career at the forefront of cancer immunology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Systems Approach to Discover Sensors and Regulators of the Mitochondrial Genome
  • 批准号:
    10589232
  • 项目类别:
  • 资助金额:
    $12.5万
  • 财政年份:
    2023
  • 负责人:
    Sneha Prakash Rath
  • 依托单位:
Molecular Determinants of Mitochondrial Genome Abundance and Integrity
  • 批准号:
    10334436
  • 项目类别:
  • 资助金额:
    $10.29万
  • 财政年份:
    2019
  • 负责人:
    Sneha Prakash Rath
  • 依托单位:
Molecular Determinants of Mitochondrial Genome Abundance and Integrity
  • 批准号:
    10091405
  • 项目类别:
  • 资助金额:
    $9.82万
  • 财政年份:
    2019
  • 负责人:
    Sneha Prakash Rath
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: